CD274 and neoplasm: A nanoboron formulation delivering PD-L1 siRNA has been shown to combine Boron Neutron Capture Therapy (BNCT) with immunotherapy, producing synergistic antitumor effects and markedly suppressing tumor growth and metastasis in triple-negative breast cancer models [122].